Agilent Technologies Inc (NYSE:A) has been given an average rating of “Buy” by the seventeen brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have issued a buy rating on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $83.92.
Several analysts have commented on the stock. Cowen lifted their price objective on shares of Agilent Technologies from $80.00 to $90.00 and gave the company an “outperform” rating in a research note on Tuesday, March 26th. Deutsche Bank increased their price objective on Alphabet from $1,300.00 to $1,400.00 and gave the company a “buy” rating in a report on Wednesday, May 15th. Bank of America raised First Horizon National from an “underperform” rating to a “neutral” rating and set a $16.00 price objective for the company in a report on Tuesday. Barclays set a $330.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Monday. Finally, ValuEngine raised Valmont Industries from a “sell” rating to a “hold” rating in a report on Friday, July 12th.
A number of institutional investors have recently bought and sold shares of the stock. Stratos Wealth Partners LTD. lifted its holdings in shares of Agilent Technologies by 2.7% in the first quarter. Stratos Wealth Partners LTD. now owns 31,792 shares of the medical research company’s stock valued at $2,555,000 after buying an additional 850 shares during the period. TimesSquare Capital Management LLC raised its position in Agilent Technologies by 0.7% during the first quarter. TimesSquare Capital Management LLC now owns 1,007,700 shares of the medical research company’s stock valued at $80,999,000 after purchasing an additional 7,200 shares in the last quarter. Nordea Investment Management AB raised its position in Agilent Technologies by 510.5% during the first quarter. Nordea Investment Management AB now owns 112,292 shares of the medical research company’s stock valued at $9,028,000 after purchasing an additional 93,898 shares in the last quarter. Mason Street Advisors LLC raised its position in Agilent Technologies by 0.8% during the first quarter. Mason Street Advisors LLC now owns 45,312 shares of the medical research company’s stock valued at $3,642,000 after purchasing an additional 370 shares in the last quarter. Finally, Envestnet Asset Management Inc. raised its position in Agilent Technologies by 7.6% during the first quarter. Envestnet Asset Management Inc. now owns 144,566 shares of the medical research company’s stock valued at $11,620,000 after purchasing an additional 10,188 shares in the last quarter.
Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Tuesday, May 14th. The medical research company reported $0.71 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.72 by ($0.01). The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.27 billion. Agilent Technologies had a return on equity of 19.71% and a net margin of 22.25%. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.65 earnings per share. On average, equities analysts anticipate that Agilent Technologies will post 3.05 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 24th. Investors of record on Tuesday, July 2nd will be given a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.94%. The ex-dividend date of this dividend is Monday, July 1st. Agilent Technologies’s dividend payout ratio is presently 23.66%.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
See Also: Cash Asset Ratio
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.